Mirabody-IR700: A novel EGFR-targeting platform for photoimmunotherapy [0.03%]
新型EGFR靶向光免疫治疗平台Mirabody-IR700
Citra R A P Palangka,Motofumi Suzuki,Ayaka Kanai et al.
Citra R A P Palangka et al.
Near-infrared photoimmunotherapy (NIR-PIT) is a targeted cancer treatment based on antibody-IR700, a photoabsorber conjugate. NIR-PIT with IR700-conjugated anti-EGFR antibodies is currently used in clinical practice; however, the developmen...
Individual differences in brain cocaine pharmacokinetics predict cocaine intake patterns in rats [0.03%]
大鼠大脑中可卡因药代动力学的个体差异决定了其摄取模式
Dana Conlisk,Gabriela Goncalves Valente,Jean-François Wiart et al.
Dana Conlisk et al.
Pharmacokinetic factors play a critical role in cocaine use. Previous work mainly examined externally driven pharmacokinetic manipulations, showing that conditions producing rapid fluctuations in brain cocaine levels, such as intermittent v...
Differential cellular responses of breast cancer and non-tumorigenic mammary epithelial cells to a fullerene-doxorubicin complex [0.03%]
富勒醇-多柔比星复合物在乳腺癌和非致瘤性乳腺上皮细胞中产生不同的细胞反应
Natalia Zaręba-Wdowiak,Monika Ołdakowska,Magdalena Wojtas et al.
Natalia Zaręba-Wdowiak et al.
Breast cancer remains a leading cause of cancer-related mortality among women, with triple-negative breast cancer (TNBC) representing a particularly aggressive subtype with limited therapeutic options. Doxorubicin (DOX), a widely used chemo...
Retraction notice to "Induction of G2/M phase arrest and apoptosis by a new tetrahydroingenol diterpenoid from Euphorbia erythradenia Bioss. in melanoma cancer cells" [Biomed. Pharmacother. 86 (2017), 334-342] [0.03%]
撤销论文“Euphorbia erythradenia Bioss.中新四氢ingenol二萜类化合物诱导黑素瘤癌细胞G2 / M期阻滞和凋亡[生物医学 pharmacotherapy。 86（2017年），第334-342页]”的撤稿通知
Faranak Fallahian,Mustafa Ghanadian,Mahmoud Aghaei et al.
Faranak Fallahian et al.
Retraction notice to "Panax quinquefolium saponin inhibits endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and attenuates the progression of osteoarthritis in rat" [Biomed. Pharmacother. 97 (2018) 886-894] [0.03%]
撤销《Panax quinquefolium皂苷抑制小鼠软骨细胞内质网应激诱导的凋亡及其相关炎症反应并减轻大鼠膝骨关节炎进展》[Biomed. Pharmacother. 97 (2018) 886-894]
Jun-Jun Xie,Jian Chen,Shi-Kun Guo et al.
Jun-Jun Xie et al.
Retraction notice to "Butein inhibits cancer cell growth by rescuing the wild-type thermal stability of mutant p53" [Biomed. Pharmacother. 163 (2023) 114773] [0.03%]
撤销《白桦茋通过恢复突变p53的野生型热稳定性来抑制癌细胞生长》[Biomed. Pharmacother. 163 (2023) 114773]的通知
Bin Song,Jiajian Wang,Yixin Ren et al.
Bin Song et al.
Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification [0.03%]
肌层浸润性膀胱癌的尿液生物标志物：新辅助化疗反应预测和患者分层的当前状态及潜在机会
Gisela de Miguel-García,Vicenç Ruiz de Porras,Miriam Font-Morón et al.
Gisela de Miguel-García et al.
Bladder cancer (BC) is the eleventh most diagnosed malignancy worldwide for both sexes and the sixth in men, representing a significant public health concern. It is a heterogeneous disease classified according to tumor invasion into the bla...
High-throughput screening identification of USP7 inhibitors reveals YM155 as a biologically active scaffold with in vivo antitumor efficacy [0.03%]
高通量筛选鉴定出USP7抑制剂，揭示YM155具有体内抗肿瘤活性的生物活性支架
Rita I Oliveira,Caio Franco,Miguel Mano et al.
Rita I Oliveira et al.
Targeting the ubiquitin-proteasome system has emerged as a powerful therapeutic strategy in oncology, particularly through modulation of deubiquitinating enzymes that regulate the stability of oncogenic proteins. Among these, ubiquitin-spec...
Retraction notice to "Marine actinobacteria as a drug treasure house" [Biomedicine & Pharmacotherapy 87 (2017) 46-57] [0.03%]
撤稿通知：“海洋放线菌作为药物宝库”[Biomedicine & Pharmacotherapy 87 (2017) 46-57]
Syed Shams Ul Hassan,Abdul Lateef Shaikh
Syed Shams Ul Hassan
2-deoxy-d-ribose: A multifaceted player at the crossroads of cancer metabolism [0.03%]
2-脱氧-D-核糖：癌症代谢十字路口的多面体参与者
Marie C Kersten,Marie Witt,Thorsten Stiewe et al.
Marie C Kersten et al.
Understanding metabolic interactions within the tumor microenvironment (TME) remains a major challenge in cancer research with significant clinical implications. Among the metabolites shaping the TME, 2-deoxy-D-ribose (2dDR) has emerged as ...